Overview

Efficacy and Long-Term Safety of Vildagliptin as Monotherapy in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2010-10-01
Target enrollment:
Participant gender:
Summary
This is a 2-3 period parallel group study with an adaptive element in Type 2 diabetes patients receiving vildagliptin as monotherapy.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Novartis
Treatments:
Vildagliptin